RT Journal Article
SR Electronic
T1 Estimating SARS-CoV-2 variant strain infectiousness in Japan as of March 28, 2021
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.04.11.21255283
DO 10.1101/2021.04.11.21255283
A1 Kurita, Junko
A1 Sugawara, Tamie
A1 Ohkusa, Yasushi
YR 2021
UL http://medrxiv.org/content/early/2021/04/17/2021.04.11.21255283.abstract
AB Background A variant strain of SARS-CoV-2, VOC202012/01, emerged in the UK in September, 2020. Its infectiousness was estimated as higher than that of the original strain.Object We estimated the infectiousness of the variant strain of SARS-CoV-2 in comparison to that of the original strain under conditions prevailing in Japan.Methods We estimated infectiousness through a simple susceptible–infected–recovered (SIR) model by strain. The study period was March 1–28, 2020. The information used for the study was available as of April 3, 2020.Results The estimated reproduction number of the SARS-CoV-2 variant strain was 1.799; its 95% CI was [1.642, 1.938]. The onset date of the first case in Japan was estimated as December 4 ([November 16, December 14]), 2020. However, infectiousness of the original strain was estimated as 1.123 ([1.093, 1.166]).Discussion and Conclusion We demonstrated that infectiousness increased by 0.684 or 60%, increasing from the original to the variant. That finding might be comparable to that of a study conducted in the UK. However, the difference must be monitored continuously and carefully.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe author(s) received no specific funding for this work.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All information used for this study has been published. There is therefore no ethical issue related to this study.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesMinistry of Health, Labour and Welfare, Implementation rate and positive rate of screening test for the variant strain (mechanical estimation) preliminary figures. (in Japanese) World Health Organization. Coronavirus disease (COVID-19) Weekly Epidemiological Update and Weekly Operational Update https://www.mhlw.go.jp/content/000766381.pdf https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports